Summary
• Curis, Inc. stock jumped 8.6% in after-hours trading to $1.26 after positive clinical trial results for its AML treatment.
• 62.5% of patients in the frontline study achieved undetectable minimal residual disease, bolstering investor confidence.
• Analysts maintain a “Buy” rating, indicating a favorable long-term outlook amid Curis’s ongoing challenges.
Curis, Inc. (NASDAQ: CRIS) saw an after-hours price action of $1.26, reflecting a notable increase of 8.6% from its last close of $1.16. The stock movement comes after the company provided updated clinical data from its ongoing acute myeloid leukemia (AML) triplet study, enhancing investor optimism.
Positive Clinical Outcomes from AML Study
On December 9, Curis reported that 5 out of 8 patients, or 62.5%, in its frontline triplet study achieved undetectable minimal residual disease (uMRD). This data was shared in a poster presentation at the 67th ASH Annual Meeting, highlighting the potential efficacy of emavusertib, the company’s IRAK4 and FLT3 inhibitor. The positive results have buoyed investor interest, contributing to the stock’s rise during after-hours trading.
The company’s recent earnings report showed a surprise of 21% with actual losses per share of $0.49 compared to an estimate of a $0.62 loss. This unexpected improvement adds to a more favorable outlook as Curis seeks to establish itself in the competitive biotech landscape.
Market Overview and Technical Indicators
The stock has struggled over the past year, demonstrating a year-to-date performance of -62.1%. Despite this, the recent data from the AML study has provided a much-needed boost. Curis’s 10-day average trading volume stands at approximately 99,064, indicating moderate liquidity relative to its trading history. The current Relative Strength Index (RSI) is positioned at 40.22, suggesting the stock may be entering a recovery phase.
In terms of technical analysis, the stock is trading notably below its 20-day, 50-day, and 200-day simple moving averages, reflecting a challenging performance trend over time. However, the recent uptick could signify a potential shift in momentum for the biotech firm.
Analyst Sentiment and Future Expectations
Curis holds a “Buy” rating among analysts, suggesting a more positive long-term outlook amid recent developments. Investors appear to be responding favorably to the updated clinical results, which could pave the way for improved performance in upcoming sessions.
Conclusion
With the latest clinical data now reflected in trading, investors seem to be reassessing Curis’s growth potential as they monitor the stock’s performance heading into the next session. The positive response to the data from the AML study suggests renewed optimism for Curis, a sentiment that traders will be keen to follow in the coming days.